2-(perhydroazepino)perhydroazepine | 104502-18-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: 2-(perhydroazepino)perhydroazepine
• 英文别名: 1-(Azepan-2-yl)azepane
• CAS: 104502-18-3
• 化学式: C₁₂H₂₄N₂
• mdl: MFCD20547667
• 分子量: 196.336
• InChiKey: UWSCJICCRXNKCK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  环己亚胺 、 sodium hydroxide 、 氰化钠 以6%的产率得到
  参考文献：
  名称：

  TROYANSKIJ, EH. I.;IOFFE, V. A.;NIKISHIN, G. I., IZV. AN CCCP. CEP. XIM., 1985, N 11, 2537-2546

  摘要：

  DOI：

文献信息

• Chemical compounds
  申请人：Chan Chuen

  公开号：US20060160886A1

  公开（公告）日：2006-07-20

  The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

  本发明涉及式(Ic)化合物，其制备方法，含有它们的药物组合物以及它们在医学上的应用，特别是在改善适应于Xa因子抑制剂的临床状况方面的应用。
• Nitriles and medicinal compositions containing the same as the active ingredient
  申请人：Ohmoto Kazuyuki

  公开号：US20070197510A1

  公开（公告）日：2007-08-23

  The present invention relates to a compound of formula (I) wherein Y and Z each is independently N or C; ring A is a carbocyclic group or a heterocyclic group; ring B is a heterocyclic group containing at least one nitrogen atom; R is a hydrogen atom, a substitutent, etc.; n is 0, or an integer of from 1 to 10, a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof. The compound of formula (I), a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof has an inhibitory activity against cysteine protease, and it is useful for the prophylaxis and/or treatment of a cysteine protease-related disease such as osteoporosis, etc.

  本发明涉及一种式（I）的化合物，其中Y和Z各自独立地为N或C；环A是一个碳环基团或杂环基团；环B是一个含有至少一个氮原子的杂环基团；R是氢原子、取代基等；n为0或1至10的整数，其盐、溶剂化物、N-氧化物或前药。式（I）的化合物及其盐、溶剂化物、N-氧化物或前药具有对半胱氨酸蛋白酶的抑制活性，对于预防和/或治疗半胱氨酸蛋白酶相关疾病如骨质疏松症等有用。
• NOVEL ANTI-INFLAMMATORY AGENTS
  申请人：Hansen Henrik C.

  公开号：US20120040954A1

  公开（公告）日：2012-02-16

  Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.

  本发明涉及一种新型化合物，该化合物可用于调节白细胞介素-6（IL-6）和/或血管细胞黏附分子-1（VCAM-1）的表达，并且可用于治疗和/或预防心血管和炎症性疾病及相关疾病状态，例如动脉粥样硬化、哮喘、关节炎、癌症、多发性硬化症、牛皮癣和炎症性肠病以及自身免疫疾病。此外，本发明还涉及包含该新型化合物的组合物，以及其制备方法。
• Oxidation of azacycloalkanes
  作者：�. I. Troyanskii、V. A. Ioffe、G. I. Nikishin

  DOI：10.1007/bf00956799

  日期：1985.11
• PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PDE4 MEDIATED DISEASE STATES
  申请人：AstraZeneca AB

  公开号：EP2297106A1

  公开（公告）日：2011-03-23